miR-181a与乳腺癌关系的研究进展

doi:10.3969/j.issn.1006-7795.2017.04.008

首都医科大学学报 ›› 2017, Vol. 38 ›› Issue (4): 526-529.doi: 10.3969/j.issn.1006-7795.2017.04.008

miR-181a与乳腺癌关系的研究进展

谷牧青¹, 杨春², 王利娟³, Pierre Hardy², 贾婵维¹, 阮祥燕³

1. 首都医科大学附属北京妇产医院生殖医学科, 北京 100026;
2. 蒙特利尔大学CHU-saint-Justine医院药理学系研究中心, 蒙特利尔 H3T 1C8, 加拿大;
3. 首都医科大学附属北京妇产医院妇科内分泌科, 北京 100026

收稿日期:2017-06-05 出版日期:2017-07-21 发布日期:2017-07-20
通讯作者: 贾婵维,阮祥燕 E-mail:jiachanwei@163.com;ruanxiangyan@163.com
基金资助:
国家自然科学基金（81671411），北京市自然科学基金（7162062），国家外国专家局2017年度北京市引进国外技术、管理人才项目（20171100004），北京市科技新星计划交叉学科合作项目（Z161100004916045），北京市卫生系统高层次卫生技术人才（学科带头人）（2014-2-016）

Current research studies of the relationship between miR-181a and breast cancers

Gu Muqing¹, Yang Chun², Wang Lijuan³, Pierre Hardy², Jia Chanwei¹, Ruan Xiangyan³

1. Department of Reproduction, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing 100026, China;
2. Department of Pharmacology, Research Center of CHU-saint-Justine Hospital, University of Montreal H3T 1C8, Montreal, Canada;
3. Department of Gynecological Endocrinology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing 100026, China

Received:2017-06-05 Online:2017-07-21 Published:2017-07-20
Supported by:
This study was supported by National Natural Science Foundation of China(81671411), Natural Science Foundation of Beijing (7162062);Foreign Technical and Administrative Talent Introduction Project in 2017;State Administration of Foreign Experts Affairs, the P. R. of china(20171100004); Beijing Nova Program Interdisciplinary Studies Cooperative Projects (Z161100004916045); Clinical Technique Innovation Project of Beijing Municipal Administration of Hospitalist (2014-2-016)

摘要/Abstract

摘要： 微小RNA（microRNAs，miRNAs）是一类高度保守的非编码单链RNA，通过与靶基因mRNA的3'非编码区特异性结合，在转录后水平沉默靶基因表达，从而发挥着功能。一些研究表明miR-181a的表达与肿瘤密切相关，对肿瘤的形成、侵袭及转移起着很重要的作用。miR-181a在乳腺癌中的作用，目前还有诸多争议，一些研究表明miR-181a具有抑癌基因的作用，而另一些研究发现其具有促进肿瘤生成、转移的作用。本文就其在乳腺癌细胞中发挥作用的潜在作用机制，以及其未来临床应用可能，如作为肿瘤标志物用于早期乳腺癌诊断，评估病人化学药物治疗（以下简称化疗）敏感性，作为辅助化疗药物增强化疗敏感性药物等方面进行综述。

关键词: 乳腺癌, miR-181a, 肿瘤标志物, 诊断, 化疗

Abstract: MicroRNAs (miRNAs) are highly conserved non-coding single stranded RNAs. miRNAs participate in fundamental biological processes and pathophysiological processes by silencing their target mRNAs expression through binding to their 3' untranslated regions (3'-UTRs). Emerging studies have shown that alterations of miR-181a levels are involved in the initiation, progression and metastasis of human cancers. Some studies have indicated that miR-181a serves as tumor suppressors, and others have revealed the oncogenic roles of miR-181a. A growing number of evidence has linked the pathological role of miR-181a to breast cancer. Here, we specifically summarize the various published data of the links between miR-181a and breast cancers, and to explain the potential clinical application of miR-181a. miR-181a may be used as a clinically diagnostic biomarkers of breast cancer for early stage diagnosis, for evaluation of the chemotherapy sensitivity, and for directing the clinical treatment in patients.

Key words: breast cancer, miR-181a, biomarkers, diagnosis, chemotherapy

中图分类号:

R737.9

谷牧青, 杨春, 王利娟, Pierre Hardy, 贾婵维, 阮祥燕. miR-181a与乳腺癌关系的研究进展[J]. 首都医科大学学报, 2017, 38(4): 526-529.

Gu Muqing, Yang Chun, Wang Lijuan, Pierre Hardy, Jia Chanwei, Ruan Xiangyan. Current research studies of the relationship between miR-181a and breast cancers[J]. Journal of Capital Medical University, 2017, 38(4): 526-529.

参考文献

[1] Bartel D P. MicroRNAs: genomics, biogenesis, mechanism, and function[J]. Cell, 2004, 116(2): 281-297.
[2] Sun X, Sit A, Feinberg M W. Role of miR-181 family in regulating vascular inflammation and immunity[J]. Trends Cardiovasc Med, 2014, 24(3): 105-112.
[3] Chen G, Zhu W, Shi D, et al. MicroRNA-181a sensitizes human malignant glioma U87MG cells to radiation by targeting Bcl-2[J]. Oncol Rep, 2010, 23(4): 997-1003.
[4] Gao W, Yu Y, Cao H, et al. Deregulated expression of miR-21, miR-143 and miR-181a in non small cell lung cancer is related to clinicopathologic characteristics or patient prognosis[J]. Biomed Pharmacother, 2010, 64(6): 399-408.
[5] Parikh A, Lee C, Joseph P, et al. microRNA-181a has a critical role in ovarian cancer progression through the regulation of the epithelial-mesenchymal transition[J]. Nat Commun, 2014, 5: 2977.
[6] Niu J, Xue A, Chi Y, et al. Induction of miRNA-181a by genotoxic treatments promotes chemotherapeutic resistance and metastasis in breast cancer[J]. Oncogene, 2016, 35(10): 1302-1313.
[7] Li Y, Kuscu C, Banach A, et al. miR-181a-5p inhibits cancer cell migration and angiogenesis via downregulation of matrix metalloproteinase-14[J]. Cancer Res, 2015, 75(13): 2674-2685.
[8] 张淑群,魏嫒嫒,马一楠,等.uPA在三阴性乳腺癌组织中的表达及临床意义[J].现代肿瘤医学,2014,22(7):1567-1569.
[9] Mahanivong C, Yu J, Huang S. Elevated urokinase-specific surface receptor expression is maintained through its interaction with urokinase plasminogen activator[J]. Mol Carcinog, 2007, 46(3): 165-175.
[10] Noh H, Hong S, Dong Z, et al. Impaired microRNA processing facilitates breast cancer cell invasion by upregulating urokinase-type plasminogen activator expression[J]. Genes & Cancer, 2011, 2(2): 140-150.
[11] Wei J L, Li Y C, Ma Z L, et al. miR-181a-5p promotes anoikis by suppressing autophagy during detachment induction in the mammary epithelial cell line MCF10A[J]. Protein & Cell, 2016, 7(4): 305-309.
[12] Taylor M A, Sossey-Alaoui K, Thompson C L, et al. TGF-β upregulates miR-181a expression to promote breast cancer metastasis[J]. J Clin Invest, 2013, 123(1): 150-163.
[13] Wang Y, Yu Y, Tsuyada A, et al. Transforming growth factor-β regulates the sphere-initiating stem cell-like feature in breast cancer through miRNA-181 and ATM[J]. Oncogene, 2011, 30(12): 1470-1480.
[14] Bisso A, Faleschini M, Zampa F, et al. Oncogenic miR-181a/b affect the DNA damage response in aggressive breast cancer[J]. Cell Cycle, 2013, 12(11): 1679-1687.
[15] Banin S, Moyal L, Shieh S, et al. Enhanced phosphorylation of p53 by ATM in response to DNA damage[J]. Science, 1998, 281(5383): 1674-1677.
[16] Strotbek M, Schmid S, Sánchez-González I, et al. miR-181 elevates Akt signaling by co-targeting PHLPP2 and INPP4B phosphatases in luminal breast cancer[J]. Int J Cancer, 2017, 140(10): 2310-2320.
[17] 中国抗癌协会乳腺癌专业委员会. 中国抗癌协会乳腺癌诊治指南与规范(2015 版)[J]. 中国癌症杂志, 2015, 25(9): 692-754.
[18] Cortez M A, Calin G A. MicroRNA identification in plasma and serum: a new tool to diagnose and monitor diseases[J]. Expert Opin Biol Ther, 2009, 9(6): 703-711.
[19] Guo L J, Zhang Q Y. Decreased serum miR-181a is a potential new tool for breast cancer screening[J]. Int J Mol Med, 2012, 30(3): 680-686.
[20] Ferracin M, Lupini L, Salamon I, et al. Absolute quantification of cell-free microRNAs in cancer patients[J]. Oncotarget, 2015, 6(16): 14545-14555.
[21] McDermott A M, Miller N, Wall D, et al. Identification and validation of oncologic miRNA biomarkers for luminal A-like breast cancer[J]. PLoS One, 2014, 9(1): e87032.
[22] Zhu Y, Wu J, Li S, et al. The function role of miR-181a in chemosensitivity to adriamycin by targeting Bcl-2 in low-invasive breast cancer cells[J]. Cell Physiol Biochem, 2013, 32(5): 1225-1237.
[23] Del Bufalo D, Biroccio A, Trisciuoglio D, et al. Bcl-2 has differing effects on the sensitivity of breast cancer cells depending on the antineoplastic drug used[J]. Eur J Cancer, 2002, 38(18): 2455-2462.
[24] Jiao X, Zhao L, Ma M, et al. miR-181a enhances drug sensitivity in mitoxantone-resistant breast cancer cells by targeting breast cancer resistance protein (BCRP/ABCG2)[J]. Breast Cancer Res Treat, 2013, 139(3): 717-730.
[25] Selever J, Gu G, Lewis M T, et al. Dicer-mediated upregulation of BCRP confers tamoxifen resistance in human breast cancer cells[J]. Clin Cancer Res, 2011, 17(20): 6510-6521.
[26] Niu J, Xue A, Chi Y, et al. Induction of miRNA-181a by genotoxic treatments promotes chemotherapeutic resistance and metastasis in breast cancer[J]. Oncogene, 2016, 35(10): 1302-1313.
[27] Foulkes W D, Smith I E, Reis-Filho J S. Triple-negative breast cancer[J]. N Engl J Med, 2010, 363(20): 1938-1948.
[28] Carey L, Winer E, Viale G, et al. Triple-negative breast cancer: disease entity or title of onvenience?[J]. Nat Rev Clin Oncol, 2010, 7(12): 683-692.
[29] 郭晓龙,郑美珠,左文述,等.三阴性乳腺癌靶向治疗的研究前景[J].中华肿瘤防治杂志,2014,21(21):1751-1756.
[30] 杜娟,阮祥燕.三阴乳腺癌的特点及研究进展[J].首都医科大学学报,2015,36(4):578-582.

miR-181a与乳腺癌关系的研究进展

Current research studies of the relationship between miR-181a and breast cancers

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	罗诗雨, 李眉, 罗莎, 王爽, 张娟, 李萌, 南潇, 鲜军舫. ¹⁸F-FDG PET/CT在脉络膜黑色素瘤与脉络膜转移癌鉴别诊断中的应用价值[J]. 首都医科大学学报, 2022, 43(6): 867-872.
[2]	钱坤, 赵昕, 谭晓刚, 田笑如, 刘幸生, 张毅. 电子计算机断层扫描引导下经皮肺穿刺活检磨玻璃结节的诊断价值[J]. 首都医科大学学报, 2022, 43(4): 558-563.
[3]	谭晓刚, 张毅. 电磁导航支气管镜在肺外周病变诊断及治疗的临床应用[J]. 首都医科大学学报, 2022, 43(4): 570-575.
[4]	田明, 孔秋, 候晓晓, 苗劲蔚. 良、恶性卵巢甲状腺肿的临床和病理特征分析[J]. 首都医科大学学报, 2022, 43(3): 343-349.
[5]	赵越, 阮祥燕, 程姣姣, 谷牧青, 许新, 王月姣. 乳腺癌中PGRMC1表达与临床病理参数的相关性[J]. 首都医科大学学报, 2022, 43(3): 350-356.
[6]	侯磊, 王小新, 刘丽恒, 张为远, 王欣. 134例生长受限胎儿产前诊断结果分析[J]. 首都医科大学学报, 2022, 43(3): 375-379.
[7]	吕晗, 赵鹏飞, 尹红霞, 王振常. 耳科影像学的关键技术创新和应用——2020年度国家科学技术进步奖二等奖[J]. 首都医科大学学报, 2022, 43(1): 13-16.
[8]	魏常胜, 骆成玉, 张树琦. 环乳晕切口联合乳腔镜腋窝淋巴结清扫在早期乳腺癌保乳手术中的应用[J]. 首都医科大学学报, 2021, 42(6): 1014-1020.
[9]	高广程, 孙欣, 许颖, 禚风麟. 女性外阴巨大溃疡临床分析和经验总结[J]. 首都医科大学学报, 2021, 42(6): 1046-1052.
[10]	中华预防医学会妇女保健分会; 中国人体健康科技促进会妇科内分泌与生育力促进专委会. 乳腺癌患者选择性雌激素受体调节剂治疗相关子宫内膜安全管理的中国专家共识(2021版)[J]. 首都医科大学学报, 2021, 42(4): 672-677.
[11]	刘翕然, 徐雁, 王维治, 王丽华, 张美妮, 李春阳, 董会卿, 李国忠, 刘洪波, 付锦, 金涛, 管阳太, 檀国军, 郭力, 张星虎. 中国多发性硬化临床特点及诊断难点分析[J]. 首都医科大学学报, 2021, 42(3): 360-366.
[12]	阮祥燕, 杨瑜, 卢丹, 杜娟, 程姣姣, 谷牧青, 李扬璐, 金凤羽, 段微, 代荫梅, 鞠蕊, 许新, MatthiasKorell, AlfredO.Mueck. 中国首例乳腺癌患者冻存卵巢组织移植成功报道及文献复习[J]. 首都医科大学学报, 2021, 42(2): 177-182.
[13]	侯磊, 李介岩, 邢宇, 刘丽恒, 王欣. 22q11.2微缺失综合征胎儿的超声特征[J]. 首都医科大学学报, 2021, 42(2): 183-187.
[14]	王观筠, 杨晖, 陈佳欣, 肖文田, 李灿, 姚树林, 王瑞民, 徐白萱. 眼附属器淋巴瘤¹⁸F-FDG PET/CT的代谢特征及其与临床分期的相关性[J]. 首都医科大学学报, 2021, 42(1): 21-25.
[15]	杨阳, 康骅, 赵菁, 凌煜玮, 赵烨, 王亚军, 戎冬冬. 术前乳腺MRI对乳腺癌保乳手术切缘评估的回顾性分析[J]. 首都医科大学学报, 2020, 41(6): 943-953.